ArticleDiscover oncology2025
Circulating metabolic biomarkers mediated causal relationship between gut microbiota and bladder cancer: a two-step mendelian randomization study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Gut microbiotas attributed to disorders and diseases of the gastrointestinal tract, colorectal cancer, bladder cancer: Geographical factors, inflammation, metabolic toxic.World journal of gastrointestinal pharmacology and therapeutics · 2026Article
- Fecal microbiota transplantation: a novel strategy and challenges in the adjuvant treatment of bladder Cancer.Frontiers in microbiology · 2026Review
- Mendelian randomization analysis of gut microbiota-immune cell interactions in malignant neoplasm of nasopharynx.AMB Express · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundDysbiosis of the gut microbiota (GM) has been reported to be associated with cancers, including bladder cancer (BLCA). However, the specific causal relationship between GM and BLCA, as well as the mediating role of circulating metabolic biomarkers (CMBs), has remained unclear. Therefore, we aimed to elucidate the causal relationship among GM, CMBs, and BLCA, through a mendelian randomization (MR) approach.
methodThe summary statistics of 473 GM (n = 5959) and 233 CMBs (n = 136,016) from the NHGRI-EBI GWAS Catalog, and BLCA (cases n = 2053 and controls n = 287,137) from the FinnGen study were leveraged for our research. Bidirectional MR analysis was conducted to investigate the causal link between GM and BLCA, and two-step MR (TSMR) was employed to identified potential mediating CMBs. The inverse-variance weighted (IVW) was primarily utilized for effect estimation. Additionally, the Cochrane's Q test was used to evaluate heterogeneity, and the MR-Egger method was employed to evaluate pleiotropy.
resultThe study revealed that 15 GM and 12 CMBs were causally associated with BLCA (p < 0.05). Specially, dorea was found to significantly increase the risk of developing BLCA (OR = 2.20, 95% CI: 1.29-3.75). Furthermore, TSMR analysis indicated that total cholesterol levels in small HDL and cholesterol esters in small HDL mediate the causal relationship between dorea and BLCA, with mediated proportions of 2.46% and 2.14%, respectively.
conclusionThe findings of this study provide compelling evidence supporting the mediating role of CMBs in the causal relationship on GM and BLCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.